ORIC Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company was founded in 2014 and is headquartered in South San Francisco, California. ORIC Pharmaceuticals is a publicly traded company listed on the Nasdaq Stock Exchange under the ticker symbol "ORIC."
ORIC Pharmaceuticals is dedicated to addressing the mechanisms of resistance in cancer, particularly for patients who have developed resistance to existing therapies. The company's research and development efforts center around developing novel treatments that target specific resistance pathways, with the goal of improving patient outcomes and quality of life.
The company's flagship drug is ORIC-101, an investigational small molecule antagonist of the GR. ORIC-101 is being evaluated in clinical trials for the treatment of several types of solid tumors, including prostate, breast, ovarian, and colorectal cancers. The drug has shown promising results in preclinical studies, demonstrating its potential to overcome treatment resistance and enhance the efficacy of existing therapies.
In addition to ORIC-101, the company has a robust pipeline of other novel therapies targeting resistance pathways in cancer. This includes ORIC-533, an inhibitor of CD73, which is involved in immune evasion mechanisms, and other programs targeting key drivers of resistance in cancer cells.
ORIC Pharmaceuticals' commitment to advancing innovative therapies for cancer treatment and its focus on targeting resistance mechanisms make it a prominent player in the field of oncology. The company's efforts to address treatment resistance have the potential to significantly impact patient outcomes and improve the standard of care for cancer patients.